Double-Layer Opioid Tablets for Side Effect Management

Solution Overview

Problem

Current opioid-based pain management formulations suffer from severe side effects such as nausea, vomiting, constipation, and respiratory depression, which limit their long-term use and patient quality of life, despite efforts to mitigate these issues through co-administration of antiemetics and opioid antagonists.

Innovation Solution

Development of solid oral immediate-release tablets with opioid agonists and antagonists in separate layers, where the antagonist is administered in minimal doses to rapidly block side-effect receptors before the agonist binds, using specific excipients and a double-layer tablet press for optimal absorption and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If opioid agonists are administered to control pain, then analgesic efficacy is improved, but severe side effects such as nausea, vomiting, constipation, and respiratory depression occur

Engineering Contradiction:

Improveanalgesic efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The tablet is divided into two distinct layers: a first layer containing the opioid agonist and a second layer containing the opioid antagonist. This segmentation allows the two substances to be administered simultaneously while remaining physically separated, enabling the antagonist to block side-effect receptors without completely preventing the agonist's analgesic action.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The opioid antagonist is positioned in a separate layer to preemptively block opioid receptors that mediate side effects. By having the antagonist ready in the second layer, it can counteract the harmful effects of the agonist before they fully manifest, while still allowing therapeutic benefit.

Inventive Principle:

Principle #9Preliminary anti-action

2Object-affected harmful factors

If opioid antagonists are co-administered with agonists to reduce side effects, then tolerability is improved, but analgesic efficacy may be compromised

Engineering Contradiction:

Improveside effectsVSAvoidanalgesic efficacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The tablet structure provides different local qualities in different layers: the first layer is optimized for agonist delivery to provide analgesia, while the second layer is optimized for antagonist delivery to minimize side effects. This spatial differentiation of function allows each component to perform its specific role effectively.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The antagonist is used in a minimal dose (0.005 mg) compared to the agonist, providing just enough blocking action to reduce side effects without completely preventing the agonist's therapeutic effect. This partial action maintains analgesic efficacy while improving tolerability.

Inventive Principle:

Principle #16Partial or excessive action

3Ease of manufacture

If mixed formulations of agonist and antagonist are used, then manufacturing is simplified, but selective receptor blocking is reduced

Engineering Contradiction:

Improveformulation mixingVSAvoiddrug distribution

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The tablet is divided into two distinct layers: a first layer containing the opioid agonist and a second layer containing the opioid antagonist. This segmentation allows the two substances to be administered simultaneously while remaining physically separated, enabling the antagonist to block side-effect receptors without completely preventing the agonist's analgesic action.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentEP2549984B1Double-layer pharmaceutical formulations containing opioid agonists and antagonists

Publication Date: 2015.03.18 L MOLTENI & C DEI FRAT ALITTI - SOC DI

AI summary

Immediate-release formulations are described, consisting of double-layer tablets wherein one layers contains an opioid agonist and the other an opioid antagonist.